Coronavirus vaccine by Oxford-AstraZeneca produces immune response among adults
A promising vaccine candidate developed at the University of Oxford and manufactured by AstraZeneca has shown promise in terms of the strength of the immune response it elicits from older and younger adults. AstraZeneca released the information based on results from clinical trials. In addition to a strong immune response, older people also had a low incidence of adverse reactions, which is an important factor given that age group’s risk of severe disease. A person’s immune response is what offers protection from the virus, so a vaccine candidate’s ability to trigger one is critical.
Published: October 26, 2020
Global NewsRead Article